BMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $40.00 (from $34.00) while maintaining a Market Perform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Pacira Pharmaceuticals (PCRX) PT Raised to $43 at Mizuho SecuritiesAugust 7, 2018 4:11 AM Pacira Pharmaceuticals (PCRX) PT Raised to $85 at WedbushAugust 6, 2018 7:48 AM Pacira Pharmaceuticals (PCRX) PT Raised to $50 at RBC CapitalAugust 3, 2018 7:56 AM Needham & Company Upgrades Pacira Pharmaceuticals (PCRX) to Buy; 'All Signs Point to a Significant Exparel Growth Inflection'August 3, 2018 7:27 AM Pacira Pharmaceuticals (PCRX) PT Raised to $53 at Seaport Global SecuritiesAugust 3, 2018 7:23 AM Pacira Pharmaceuticals (PCRX) PT Raised to $50 at BarclaysAugust 3, 2018 5:09 AM Form 10-Q Pacira Pharmaceuticals, For: Jun 30August 2, 2018 3:41 PM Pacira Pharma (PCRX) Tops Q2 EPS by 17c, Beats on Revenues; Offers FY18 Revenue Outlook Above ConsensusAugust 2, 2018 8:14 AM Form 8-K Pacira Pharmaceuticals, For: Aug 02August 2, 2018 8:05 AM Pacira Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial ResultsAugust 2, 2018 8:00 AM